New York, new York (PRWEB) May 14, 2014
As tens of thousands of vaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/) continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that the Canadian regulator, Health Canada, has issued an alert detailing the serious risks associated with transvaginal mesh devices used to treat pelvic organ prolapse and stress urinary incontinence. In a May 13th Notice to Hospitals, the agency said it continues to receive reports of serious and life-altering complications involving these products, including complaints of acute or chronic pain, mesh erosion (extrusion or exposure), mesh contraction (shrinkage) infection, voiding dysfunction, dyspareunia (pain during sexual intercourse), organ or blood vessel perforation, neuromuscular damage, bleeding or hemorrhage, and recurrent prolapse or incontinence.*
“Our Firm is representing hundreds of women who have allegedly suffered transvaginal mesh complications similar to those described in the Health Canada alert,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free legal reviews to women who suffered mesh erosion, pain, scarring, infection and other serious vaginal mesh complications, allegedly due to transvaginal mesh products manufactured by American Medical Systems, Inc., Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc.
Transvaginal Mesh Complications
The Health Canada notification comes just days after the U.S. Food & Drug Administration (FDA) proposed reclassifying transvaginal mesh used in prolapse repair as a high-risk medical device. According to a statement released by the agency on April 29th, the proposed reclassification was prompted by a review which “identified clear risks associated with surgical mesh for the transvaginal repair of pelvic organ prolapse.”
According to court documents, more than 50,000 vaginal mesh lawsuits have been filed in multiple litigations currently underway in U.S. District Court, Southern District of West Virginia, including American Medical Systems, Inc. (MDL No. 2325), Boston Scientific Corp. (MDL No. 2326), C.R. Bard, Inc. (MDL No. 2187) and Ethicon, Inc. (MDL No. 2327). Jeffrey S. Grand, a partner with Bernstein Liebhard LLP, is serving on the Plaintiffs’ Steering Committee for these proceedings. All of the complaints pending in the Southern District of West Virginia allege that the companies’ transvaginal mesh products caused thousands of women to suffer debilitating injuries, and accuse the defendants of failing to provide adequate warnings regarding their risk.
In addition to his work on the federal proceeding, Mr. Grand is also serving as Co-Liaison Counsel in two multicounty litigations underway in New Jersey Superior Court for transvaginal mesh lawsuits involving products marketed by C.R. Bard and Ethicon. He was also a member of the Plaintiff’s trial team on the first Ethicon trial in that proceeding, which ended in March with a jury awarding $11 million in compensatory and punitive damages to a woman who was harmed by the Ethicon Gynecare Prolift device. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)
Alleged victims of serious transvaginal mesh complications may be entitled to file their own vaginal mesh lawsuit against the company that marketed the device. To learn more about this ongoing litigation, please visit Bernstein Liebhard LLP’s website. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39475a-eng.php, Health Canada, May 13, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP